BREAKOUT STOCK ALERT UPDATE $VXRT - Vaxart, Inc. - Common Stock Initial Alert Price: $6.8 Price High: $12.74 % Gains/Losses: 87.35% (+66.85% More Than Expected) Potential Stop Loss: $12.103 VXRT is currently down 58.85% in today's trading session after reporting that neutralizing antibodies were not detected in volunteers after a single dose of its experimental...
A phase two study is expected “in the next couple of months,” Source: www.cnbc.com
I wasn't able to get into $VXRT before, and now thanks to a recent market overreaction, I think this is a great dip opportunity and will pickup support levels that will cause a short squeeze soon. RSI shows way oversold, and look at the performance day to day. That said, please invest at your own risk and do your own due diligence. Everything I say is on an...
Trade with care. Disclaimer: The analysis provided is purely informative and it should not be used as financial advice. We do not recommend making hurried trading decisions. You should always understand the risk that trading implies and that PAST PERFORMANCE IS NOT NECESSARILY INDICATIVE OF FUTURE RESULTS.
BREAKOUT STOCK ALERT UPDATE $VXRT - Vaxart, Inc. - Common Stock Initial Alert Price: $6.8 Price High: $24.9 % Gains/Losses: 266.18% (+245.85% More Than Expected) Potential Stop Loss: $23.655 Wanted to give an update on VXRT after the stock provided us with a 266.18% Gain on our initial trade alert on Jan. 14th and up another 100% from yesterday's trade alert...
BREAKOUT STOCK ALERT UPDATE $VXRT - Vaxart, Inc. - Common Stock Initial Alert Price: $6.8 Price High: $15.8 % Gains/Losses: 132.35% (+111.85% More Than Expected) Potential Stop Loss: $15.01 VXRT hit $15.80 at it's high in today's trading session on pure moment as there has not been any press releases disclosing any news to explain the price action. This is our...
Inverse head & shoulders Weekly MACD hidden bullish divergence Stop = Below support line Target = 0.618 fib extension (Could head higher and stall at the resistance or even achieve the measured move of the IHS!)
A little-known biotech is trying its hand at developing a coronavirus vaccine. Can it succeed? over the past year, Vaxart stock has soared over 1,250% because of its spot in the lucrative coronavirus vaccine race. Its stock performance even outpaced those of biotechs that have already brought their coronavirus vaccines to market, such as Moderna and...
01/28/2021--------- BULL FLAG ON DAILY 01-29-2021-------BULL FLAG ON HOURLY FEBRUARY 3RD PRESENTATION ON CONFERENCE WITH DR. FAUCI AND OTHER LEGENDS ORAL VACCINE ------ COVID 19 PILL VACCINE ----- NOROVIRUS ----- FLU---- JNJ COLLABORATION---- NEXT WEEK IF FOLLOWED THE TREND AND NEWS are POSITIVE --- $16 IS EASY !!! IF FALL DOWN --- WILL GO TO $10.45 AND STAY...
There are many ways to look at why technically this stock is poised for a potential breakout to the upside. First of all I am long 3200 shares at 6.74 so am I biased? Maybe. The stock is clearly in an uptrend, 7.60 is my short - term price target, $8 and 8.50 directly thereafter with significant upside beyond that. Pattern wise, the chart is coiling nicely. ...
Bullish Pennant Pros: Descending volume during formation PPS above 50MA and 200MA RS above 0, and ascending ATR Ascending R/R ratio above 7 200MA ascending 250RSI above 50 If confirmed: PT = 24.92$
VXRT looks like it has potential to break higher
There is a head and chowders on the graph. Also we have a bullish triangle, which has broke up. My T1 is 12, T2 is 14.50. It is NOT a recommendation of a trade!
Earnings Estimated on 12-11 BMO.. Possible stop Inverse Head and shoulders patterns are reliable as a rule.. Head is at 3.50.. LS is 4.5.. RS is 5.28.. Some prefer the RS to be higher than the LS as they say a better outcome is acheived This is not to long entry level and the neckline is resistance until price is above it, then the neckline becomes...
BUY VXRT - VAXART INC- STRONG BUY ON WEEKLY CHART
See a clear inverse head and shoulders chart layout. My first take profit will be at the first sign of resistance. Comment what you think. -Not Financial Advice